0 5 HIV-1 HIV-1 NNP 6 14 envelope envelope NN 15 28 glycoproteins glycoprotein NNS 29 35 induce induce VBP 36 46 activation activation NN 47 49 of of IN 50 59 activated activate VBN 60 69 protein-1 protein-1 NN 70 72 in in IN 73 77 CD4+ cd4+ JJ 78 79 T t NN 80 85 cells cell NNS 86 87 [ [ ( 87 96 published publish VBN 97 104 erratum erratum NN 105 112 appears appear VBZ 113 115 in in IN 116 117 J J NNP 118 122 Biol Biol NNP 123 127 Chem Chem NNP 128 132 1995 1995 CD 133 136 Dec Dec NNP 137 152 1;270(48):29038 1;270(48):29038 CD 152 153 ] ] ) 155 165 Activation activation NN 166 168 of of IN 169 172 CD4 CD4 NNP 173 181 positive positive JJ 182 183 T t NN 184 189 cells cell NNS 190 192 is be VBZ 193 194 a a DT 195 202 primary primary JJ 203 214 requirement requirement NN 215 218 for for IN 219 224 human human JJ 225 241 immunodeficiency immunodeficiency NN 242 247 virus virus NN 248 249 ( ( ( 249 252 HIV HIV NNP 252 253 ) ) ) 254 259 entry entry NN 259 260 , , , 261 270 efficient efficient JJ 271 274 HIV HIV NNP 275 286 replication replication NN 286 287 , , , 288 291 and and CC 292 303 progression progression NN 304 306 to to TO 307 311 AIDS AIDS NNP 311 312 , , , 313 322 Utilizing utilize VBG 323 326 CD4 cd4 NN 327 335 positive positive JJ 336 337 T t NN 338 342 cell cell NN 343 348 lines line NNS 349 352 and and CC 353 361 purified purify VBN 362 363 T t NN 364 369 cells cell NNS 370 374 from from IN 375 381 normal normal JJ 382 393 individuals individual NNS 393 394 , , , 395 397 we we PRP 398 402 have have VBP 403 415 demonstrated demonstrate VBN 416 420 that that IN 421 427 native native JJ 428 436 envelope envelope NN 437 450 glycoproteins glycoprotein NNS 451 453 of of IN 454 457 HIV HIV NNP 457 458 , , , 459 461 gp gp NN 462 465 160 160 CD 465 466 , , , 467 470 can can MD 471 477 induce induce VB 478 488 activation activation NN 489 491 of of IN 492 505 transcription transcription NN 506 512 factor factor NN 512 513 , , , 514 523 activated activate VBD 524 533 protein-1 protein-1 NN 534 535 ( ( ( 535 539 AP-1 ap-1 NN 539 540 ) ) ) 540 541 . . . 542 545 The the DT 546 557 stimulatory stimulatory JJ 558 565 effects effect NNS 566 568 of of IN 569 574 gp160 gp160 NN 575 578 are be VBP 579 587 mediated mediate VBN 588 595 through through IN 596 599 the the DT 600 603 CD4 cd4 NN 604 612 molecule molecule NN 612 613 , , , 614 619 since since IN 620 629 treatment treatment NN 630 632 of of IN 633 638 gp160 gp160 NN 639 643 with with IN 644 651 soluble soluble JJ 652 659 CD4-IgG CD4-IgG NNP 660 669 abrogates abrogate VBZ 670 673 its its PRP$ 674 682 activity activity NN 682 683 , , , 684 687 and and CC 688 691 CD4 cd4 NN 692 700 negative negative JJ 701 702 T t NN 703 707 cell cell NN 708 713 lines line NNS 714 718 fail fail VBP 719 721 to to TO 722 724 be be VB 725 735 stimulated stimulate VBN 736 740 with with IN 741 746 gp160 gp160 NN 746 747 . . . 748 767 Immunoprecipitation Immunoprecipitation NNP 768 770 of of IN 771 774 the the DT 775 777 gp gp NN 778 789 160-induced 160-induced JJ 790 797 nuclear nuclear JJ 798 806 extracts extract NNS 807 811 with with IN 812 822 polyclonal polyclonal JJ 823 833 antibodies antibody NNS 834 836 to to TO 837 840 Fos Fos NNP 841 844 and and CC 845 848 Jun Jun NNP 849 857 proteins protein NNS 858 867 indicates indicate VBZ 868 872 that that IN 873 877 AP-1 ap-1 NN 878 885 complex complex NN 886 888 is be VBZ 889 898 comprised comprise VBN 899 901 of of IN 902 909 members member NNS 910 912 of of IN 913 918 these these DT 919 925 family family NN 926 928 of of IN 929 937 proteins protein NNS 937 938 . . . 939 942 The the DT 943 956 gp160-induced gp160-induced JJ 957 961 AP-1 ap-1 NN 962 969 complex complex NN 970 972 is be VBZ 973 982 dependent dependent JJ 983 987 upon upon IN 988 995 protein protein NN 996 1004 tyrosine tyrosine NN 1005 1020 phosphorylation phosphorylation NN 1021 1024 and and CC 1025 1027 is be VBZ 1028 1035 protein protein NN 1036 1057 synthesis-independent synthesis-independent JJ 1057 1058 . . . 1059 1063 This this DT 1064 1075 stimulation stimulation NN 1076 1079 can can MD 1080 1084 also also RB 1085 1087 be be VB 1088 1097 abolished abolish VBN 1098 1100 by by IN 1101 1111 inhibitors inhibitor NNS 1112 1114 of of IN 1115 1122 protein protein NN 1123 1129 kinase kinase NNP 1130 1131 C C NNP 1131 1132 , , , 1133 1136 but but CC 1137 1139 it it PRP 1140 1142 is be VBZ 1143 1153 unaffected unaffected JJ 1154 1156 by by IN 1157 1164 calcium calcium NN 1165 1172 channel channel NN 1173 1180 blocker blocker NN 1181 1183 or or CC 1184 1196 cyclosporine cyclosporine NN 1197 1198 A a NN 1198 1199 . . . 1200 1204 This this DT 1205 1210 gp160 gp160 NN 1211 1220 treatment treatment NN 1221 1230 adversely adversely RB 1231 1238 affects affect VBZ 1239 1242 the the DT 1243 1253 functional functional JJ 1254 1266 capabilities capability NNS 1267 1269 of of IN 1270 1271 T t NN 1272 1277 cells cell NNS 1277 1278 : : : 1279 1292 pre-treatment pre-treatment NN 1293 1295 of of IN 1296 1300 CD4+ cd4+ JJ 1301 1302 T t NN 1303 1308 cells cell NNS 1309 1313 with with IN 1314 1319 gp160 gp160 NN 1320 1323 for for IN 1324 1325 4 4 CD 1326 1327 h h NN 1328 1330 at at IN 1331 1333 37 37 CD 1334 1341 degrees degree NNS 1342 1343 C C NNP 1344 1353 inhibited inhibit VBD 1354 1370 anti-CD3-induced anti-cd3-induced JJ 1371 1384 interleukin-2 interleukin-2 NN 1385 1394 secretion secretion NN 1394 1395 . . . 1396 1403 Effects Effect NNPS 1404 1411 similar similar JJ 1412 1414 to to TO 1415 1420 gp160 gp160 NN 1421 1425 were be VBD 1426 1430 seen see VBN 1431 1435 with with IN 1436 1444 anti-CD4 anti-cd4 JJ 1445 1448 mAb mab NN 1448 1449 . . . 1450 1453 The the DT 1454 1462 aberrant aberrant JJ 1463 1473 activation activation NN 1474 1476 of of IN 1477 1481 AP-1 ap-1 NN 1482 1484 by by IN 1485 1490 gp160 gp160 NN 1491 1493 in in IN 1494 1497 CD4 cd4 NN 1498 1506 positive positive JJ 1507 1508 T t NN 1509 1514 cells cell NNS 1515 1520 could could MD 1521 1527 result result VB 1528 1530 in in IN 1531 1544 up-regulation up-regulation NN 1545 1547 of of IN 1548 1557 cytokines cytokine NNS 1558 1568 containing contain VBG 1569 1573 AP-1 ap-1 NN 1574 1579 sites site NNS 1579 1580 , , , 1581 1585 e.g. e.g. FW 1586 1599 interleukin-3 interleukin-3 NN 1600 1603 and and CC 1604 1615 granulocyte granulocyte NN 1616 1626 macrophage macrophage NN 1627 1645 colony-stimulating colony-stimulating JJ 1646 1652 factor factor NN 1652 1653 , , , 1654 1657 and and CC 1658 1670 concurrently concurrently RB 1671 1675 lead lead VB 1676 1678 to to TO 1679 1680 T t NN 1681 1685 cell cell NN 1686 1702 unresponsiveness unresponsiveness NN 1703 1705 by by IN 1706 1716 inhibiting inhibit VBG 1717 1730 interleukin-2 interleukin-2 NN 1731 1740 secretion secretion NN 1740 1741 . . .